[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356307-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356307-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fibroblast-activation-protein-targeted-radiopharmaceuticals-recent-trends-in-cancer-diagnosis","Fibroblast activation protein-targeted radiopharmaceuticals: Recent trends in cancer diagnosis","","Fibroblast activation protein (FAP) is widely overexpressed in the tumor stroma of multiple cancers and has become a promising target for cancer imaging. FAP-targeted radiopharmaceuticals provide enhanced tumor-to-background contrast relative to traditional agents, improving diagnostic precision. This review summarizes recent advances in FAP-targeted diagnostic radiopharmaceuticals, emphasizing key advantages, development directions, and future potential for cancer detection.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fibroblast-activation-protein-targeted-radiopharmaceuticals-recent-trends-in-cancer-diagnosis/356307/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fibroblast-activation-protein-targeted-radiopharmaceuticals-recent-trends-in-cancer-diagnosis/356307.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is fibroblast activation protein (FAP) considered a promising imaging target?","Question",{"text":63,"@type":64},"FAP is highly expressed in cancer-associated fibroblasts within tumor microenvironments. Its elevated presence supports improved tumor imaging compared with conventional tracers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do FAP-targeted radiopharmaceuticals compare with 18F-FDG in diagnostic performance?",{"text":68,"@type":64},"FAP-targeted agents typically achieve better selectivity and higher tumor-to-background contrast. They also reduce false positives linked to physiological uptake seen with FDG.",{"name":70,"@type":61,"acceptedAnswer":71},"What are key examples of FAP-targeted PET radiotracers discussed in the review?",{"text":72,"@type":64},"The review highlights FAPI-02 and FAPI-04, and especially 68Ga-FAPI-04. It also discusses 18F-FAPI-04 PET/CT performance across multiple cancer types.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356307,1790173290,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":118,"preview_page_count":33,"preview_urls":145},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www.clinicalimagingscience.org](www.clinicalimagingscience.org)  \nJournal of Clinical Imaging Science  \nReview Article Nuclear Medicine  \nFibroblast activation protein-targeted  \nradiopharmaceuticals: Recent trends in cancer diagnosis  \nXiaohong Huang1, Omar Emad Ibrahim2  \n1School of Graduate Studies, Postgraduate Center, Management and Science University, 2Department of Pathology, International Medical School, Management and Science University, Shah Alam, Selangor, Malaysia.  \n*Corresponding author:  \nOmar Emad Ibrahim, Department of Pathology, International Medical School, Management and Science University, Shah Alam, Selangor, Malaysia.  \n[omar_emad@msu.edu.my](omar_emad@msu.edu.my)  \n\n| Received: 19 August 2025\u003Cbr>Accepted: 20 November 2025\u003Cbr>Published: 02 January 2026 |\n| --- |\n| DOI\u003Cbr>10.25259/JCIS_209_2025 |\n\nQuick Response Code:  \nABSTRACT  \nFibroblast activation protein (FAP), widely overexpressed in the tumor stroma of various cancers, has emerged asa promising target for cancer imaging. Radiopharmaceuticals designed to target FAP offer significantly improved tumor-to-background contrast compared to traditional imaging agents, thereby enhancing the precision of cancer detection. 􀀟is review summarizes recent advancements in FAP-targeted diagnosis radiopharmaceuticals, highlighting their advantages and future potential.  \nKeywords: Diagnosis, Fibroblast activation protein, Radiopharmaceutical  \nINTRODUCTION  \nAdvancements in molecular imaging techniques, especially positron emission tomography (PET) and single-photon emission computed tomography (SPECT), have greatly enhanced cancer diagnosis. Fibroblast activation protein (FAP), a serine protease highly expressed in cancer-associated fibroblasts (CAFs), has emerged as a promising target for tumor imaging. Compared to conventional tracers such as 2-deoxy-2[ 18F]fluoro-D-glucose ( 18F-FDG), Fibroblast activation protein (FAP)-targeted radiopharmaceuticals demonstrate superior selectivity and uptake within the tumor microenvironment, enabling more effective detection of both primary and metastatic lesions.  \nFAP BIOLOGICAL CHARACTERISTICS  \nFAP is a type II transmembrane glycoprotein expressed in a wide range of malignancies, including breast, pancreatic, and lung cancers, with particularly high levels observed in epithelial tumors. It possesses both enzymatic and non-enzymatic functions, contributing to tumor progression through multiple pathways, such as enhancing cell proliferation, invasion, angiogenesis, epithelial–mesenchymal transition, and immune evasion.[1] Elevated FAP expression is also linked to a higher risk of lymph node metastasis and poorer clinical outcomes in malignant tumors. [2] In recent years, FAP-targeted diagnosis and therapies have gained momentum in cancer research.  \n􀀟ese include small-molecule inhibitors and antibodies that suppress FAP enzymatic activity, prodrugs activated by FAP protease function, DNA vaccines for preventive immunization, and FAP-specific chimeric antigen receptor T cell therapies. [3]  \n􀀟is is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.©2026 Published by Scientific Scholar on behalf of Journal of Clinical Imaging Science  \n~~ Journal of Clinical Imaging Science • 2026 • 1 ~~  \n16(1) |  \nDEVELOPMENT OF FAP-TARGETING RADIOPHARMACEUTICALS  \nFAP-specific PET radiotracers  \n18F-FDG remains the most widely used PET imaging tracer in clinical oncology, providing insights into tumor metabolism as a glucose analog. However, its diagnostic accuracy can be limited due to high physiological uptake in normal tissues, such as the brain, and in sites of inflammation, which may lead to false-positive findings[4,5] [Table 1] . To overcome these limitations, FAP-based radiotracer","cbCaid8Mfd5xasGj","https://ap.wps.com/l/cbCaid8Mfd5xasGj","pdf",1513241,"English","# Abstract\n# Introduction\n# FAP Biological Characteristics\n# Development of FAP-Targeting Radiopharmaceuticals\n## FAP-specific PET radiotracers\n## 18F-FAPI-04 PET/CT","[{\"question\":\"Why is fibroblast activation protein (FAP) considered a promising imaging target?\",\"answer\":\"FAP is highly expressed in cancer-associated fibroblasts within tumor microenvironments. Its elevated presence supports improved tumor imaging compared with conventional tracers.\"},{\"question\":\"How do FAP-targeted radiopharmaceuticals compare with 18F-FDG in diagnostic performance?\",\"answer\":\"FAP-targeted agents typically achieve better selectivity and higher tumor-to-background contrast. They also reduce false positives linked to physiological uptake seen with FDG.\"},{\"question\":\"What are key examples of FAP-targeted PET radiotracers discussed in the review?\",\"answer\":\"The review highlights FAPI-02 and FAPI-04, and especially 68Ga-FAPI-04. It also discusses 18F-FAPI-04 PET/CT performance across multiple cancer types.\"}]","Fibroblast activation protein-targeted radiopharmaceuticals: Recent trends in cancer diagnosis | PDF",1790124542,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9a7b3399573a5b5656a955f61472ff30.webp",983,1272,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82f836dfde0bdbaa7ec6c5409949791b.webp",982,1270,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/34451cbb922eb143af8769c4c2c4134b.webp",981,1269,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8eae6e32f2dc9d41afb36acfeb9fd12.webp",980,1268]